Search

Your search keyword '"Melloni, B."' showing total 270 results
Start Over Author "Melloni, B."
270 results on '"Melloni, B."'

1. Est-il important de phénotyper les patients recevant une VNI à domicile ? Analyse des résultats des premiers 2052 patients inclus dans la Cohorte ANTADIR-GAVO2

Author

Rabec, C., primary, Cuvelier, A., additional, Cervantes, P., additional, Morelot, C., additional, Georges, M., additional, Patout, M., additional, Pontier, S., additional, Mercy, M., additional, Guillaumot, A., additional, Prigent, A., additional, Gagnadoux, F., additional, Perrin, C., additional, Lavergne, F., additional, Mallart, A., additional, Grassion, L., additional, Kessler, R., additional, Claude, F., additional, Goubert, L., additional, Jaffre, S., additional, Prigent, H., additional, Perel, A., additional, Duval, Y., additional, Sedkaoui, K., additional, Chabot, F., additional, Llontop, C., additional, Berrier, A., additional, Delrieu, J., additional, Mba, L., additional, Muir, J.F., additional, Melloni, B., additional, and Gonzalez, J., additional

Published
2024
Full Text
View/download PDF

2. Identification of Patient Profiles with High Risk of Hospital Re-Admissions for Acute COPD Exacerbations (AECOPD) in France Using a Machine Learning Model

Author

Cavailles A, Melloni B, Motola S, Dayde F, Laurent M, Le Lay K, Caumette D, Luciani L, Lleu PL, Berthon G, and Flament T

Subjects
comorbidity, rehospitalisation, decision-tree analysis, cost, Diseases of the respiratory system, RC705-779
Abstract

Arnaud Cavailles,1 Boris Melloni,2 Stéphane Motola,3 Florent Dayde,3 Marie Laurent,3 Katell Le Lay,4 Didier Caumette,5 Laura Luciani,4 Pierre Louis Lleu,6 Geoffrey Berthon,7 Thomas Flament8 1Service de Pneumologie, Institut du Thorax, CHU de Nantes, Nantes, France; 2Service de Pneumologie, CHU Dupuytren, Limoges, France; 3HEVA, Lyon, France; 4HEOR/RWE, Boehringer Ingelheim, Paris, France; 5Institutional and Hospital Partnership, Boehringer Ingelheim, Paris, France; 6Medical Affairs, Boehringer Ingelheim, Paris, France; 7CHRU Tours, Tours, France; 8Service de Pneumologie, CHRU Bretonneau, Tours, FranceCorrespondence: Marie Laurent 186 Avenue Thiers, Lyon 69006, FranceTel +33 4 72 74 25 60Email mlaurent@hevaweb.comPurpose: To characterise patients with chronic obstructive pulmonary disease (COPD) who are rehospitalised for an acute exacerbation, to estimate the cost of these hospitalisations, to characterise high risk patient sub groups and to identify factors potentially associated with the risk of rehospitalisation.Patients and Methods: This was a retrospective study using the French National Hospital Discharge Database. All patients aged ≥ 40 years hospitalised for an acute exacerbation of COPD between 2015 and 2016 were identified and followed for six months. Patients with at least one rehospitalisation for acute exacerbation of COPD constituted the rehospitalisation analysis population. A machine learning model was built to study the factors associated with the risk of rehospitalisation using decision tree analysis. A direct cost analysis was performed from the perspective of national health insurance.Results: A total of 143,006 eligible patients were hospitalised for an acute exacerbation of COPD (AECOPD) in 2015– 2016 (mean age: 74 years; 62.1% men). 25,090 (18.8%) were rehospitalised for another exacerbation within six months. In this study, 8.5% of patients died during or immediately following the index hospitalisation and 10.5% died during or immediately after rehospitalisation (p < 0.001). The specific cost of these rehospitalisations was € 5304. The overall total cost per patient of all AECOPD-related stays was € 9623, being significantly higher in patients who were rehospitalised (€ 16,275) compared to those who were not (€ 8208). In decision tree analysis, the most important driver of rehospitalisation was hospitalisation in the previous two years (contributing 85% of the information).Conclusion: Rehospitalisations for acute exacerbations of COPD carry a high epidemiological and economic burden. Since hospitalisation for an acute exacerbation is the most important determinant of future rehospitalisations, management of COPD needs to focus on interventions aimed at decreasing the rehospitalisation risk of in order to lower the burden of disease.Keywords: comorbidity, rehospitalisation, decision tree analysis, cost

Published
2020

5. Caractéristiques des patients asthmatiques sévères : données de la cohorte Palomb

Author

Jestin-Guyon, N., primary, Ouaalaya, E.H., additional, Bernady, A., additional, Berteaud, E., additional, Didier, A., additional, Dupuy-Grasset, M., additional, Guilleminault, L., additional, Le Guillou, F., additional, Melloni, B., additional, Molimard, M., additional, Nguyen, L., additional, Nocent, C., additional, Ozier, A., additional, Portel, L., additional, Prud’homme, A., additional, and Raherison-Semjen, C., additional

Published
2023
Full Text
View/download PDF

8. Impact de la mise en place d’un filtre sur les performances des pressions positives et de la ventilation non invasive

Author

Rabec, C., primary, Fresnel, E., additional, Retory, Y., additional, Zhu, K., additional, Joly, K., additional, Kerfourn, A., additional, Dudoignon, B., additional, Mendoza, A., additional, Cuvelier, A., additional, Muir, J.F., additional, Melloni, B., additional, Chabot, F., additional, Gonzalez-Bermejo, J., additional, and Patout, M., additional

Published
2022
Full Text
View/download PDF

14. EvalClin: évaluation clinique des concentrateurs d’oxygène portatif : impact de l’oxygénothérapie pulsé à l’effort

Author

Maris, J., primary, Melloni, B., additional, Rabec, C., additional, Delrieu, J., additional, Mba Mintsa, L., additional, Bonnevie, T., additional, Gravier, F.E., additional, Herengt, F., additional, Al Chikahanie, Y., additional, Foret, D., additional, Cuvelier, A., additional, Chambellan, A., additional, Gonzalez-Bermejo, J., additional, Muir, J.F., additional, and Patout, M., additional

Published
2021
Full Text
View/download PDF

15. Évaluation de l’efficacité de deux schémas thérapeutiques (incluant Clarithromycine versus Moxifloxacine) sur la négativation des cultures à 6 mois au cours des infections pulmonaires à Mycobacterium xenopi. L’essai CaMoMy

Author

Andrejak, C., primary, Veziris, N., additional, Lescure, X., additional, Mal, H., additional, Catherinot, E., additional, Vallerand, H., additional, Bouvry, D., additional, Thiberville, L., additional, Blanc, F.X., additional, Couturaud, F., additional, Philippe, B., additional, Morel, H., additional, Sanlaville, F., additional, Boutoille, D., additional, Melloni, B., additional, Dautzenberg, B., additional, Bervar, J.F., additional, Marchand-Adam, S., additional, Godet, C., additional, Bergeron, A., additional, Bourdin, A., additional, Nieves, A., additional, Bergot, E., additional, Greib, C., additional, Le Meunier, F., additional, Ampere, A., additional, Appere, C., additional, Audoly, C., additional, Bildstein, F., additional, Perel, A., additional, Cuvelier, A., additional, Priou, P., additional, Bonniaud, P., additional, Jouneau, S., additional, Pradelli, J., additional, Maitre, B., additional, Cadranel, J., additional, and Jounieaux, V., additional

Published
2021
Full Text
View/download PDF

35. Cohorte ANTADIR-GAV de patients insuffisants respiratoires nouvellement traités par ventilation non invasive à domicile en France. Résultats à 18 mois

Author

Rabec, C., primary, Cuvelier, A., additional, Melloni, B., additional, Cervantes, P., additional, Morelot, C., additional, Georges, M., additional, Pontier, S., additional, Guillaumot, A., additional, Mercy, M., additional, Gagnadoux, F., additional, Perrin, C., additional, Lavergne, F., additional, Prigent, A., additional, Mallart, A., additional, Hilbert, G., additional, Kessler, R., additional, Claude, F., additional, Goubert, L., additional, Prigent, H., additional, Jaffre, S., additional, Perel, A., additional, Llontop, C., additional, Sedkaoui, K., additional, Foret, D., additional, Mounier, L., additional, Muir, F., additional, and Gonzalez, J., additional

Published
2018
Full Text
View/download PDF

40. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Author

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, and Rosell R

Abstract

IMPORTANCE: The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) in tumor tissue. OBJECTIVE: To assess the feasibility of using circulating free DNA (cfDNA) from blood samples as a surrogate for tumor biopsy for determining EGFR mutation status and to correlate EGFR mutations in cfDNA with outcome. DESIGN, SETTING, AND PARTICIPANTS: This prespecified analysis was a secondary objective of the EURTAC trial using patients included in the EURTAC trial from 2007 to 2011 with available baseline serum or plasma samples. Patients had advanced NSCLC, oncogenic EGFR mutations in the tumor, and no prior chemotherapy for metastatic disease and were treated with erlotinib or chemotherapy. EGFR mutations were examined in cfDNA isolated from 97 baseline blood samples by our novel peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay. MAIN OUTCOMES AND MEASURES: Overall survival (OS), progression-free survival (PFS), and response to therapy were correlated with type of EGFR mutations in cfDNA. RESULTS: In samples from 76 of 97 (78%) patients with usable blood samples, EGFR mutations in cfDNA were detected. Median OS was shorter in patients with the L858R mutation in cfDNA than in those with the exon 19 deletion (13.7 [95% CI, 7.1-17.7] vs 30.0 [95% CI, 19.3-37.7] months; P < .001). Univariate analyses of patients with EGFR mutations in cfDNA identified the L858R mutation in tumor tissue or in cfDNA as a marker of shorter OS (hazard ratio [HR], 2.70 [95% CI, 1.60-4.56]; P < .001) and PFS (HR, 2.04 [95% CI, 1.20-3.48]; P = .008). For patients with the L858R mutation in tissue, median OS was 13.7 (95% CI, 7.1-17.7) months for patients with the L858R mutation in cfDNA and 27.7 (95% CI, 16.1-46.2) months for those in whom the mutation was not detected in cfDNA (HR, 2.22 [95% CI, 1.09-4.52]; P = .03). In the multivariate analysis of the 76 patients with EGFR mutations in cfDNA, only erlotinib treatment remained an independent predictor of longer PFS (HR, 0.41 [95% CI, 0.23-0.74]; P = .003). CONCLUSIONS AND RELEVANCE: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA. The L858R mutation in cfDNA may be a novel surrogate prognostic marker. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00446225.

Published
2015

42. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

Author

Fournel, Pierre, primary, Vergnenégre, Alain, additional, Robinet, Gilles, additional, Léna, Hervé, additional, Gervais, Radj, additional, Le Caer, Hervé, additional, Souquet, Pierre-Jean, additional, Chavaillon, Jean-Michel, additional, Bozonnat, Marie-Cécile, additional, Daurès, Jean-Pierre, additional, Chouaid, Christos, additional, Martel-Lafay, Isabelle, additional, Fournel, P., additional, Talabard, J.N., additional, Vergnenégre, A., additional, Melloni, B., additional, Decroisette, C., additional, Clavére, P., additional, Robinet, G., additional, Bayle, S., additional, Labat, J.P., additional, Léna, H., additional, Belleguic, C., additional, Benchalal, M., additional, Gervais, R., additional, Rivière, A., additional, Lerouge, D., additional, Souquet, P.J., additional, Gérinière, L., additional, D'Hombres, A., additional, Mornex, F., additional, Le Caer, H., additional, Tessier, E., additional, Ramos, H., additional, Chavaillon, J.M., additional, Chouaid, C., additional, Touboul, E., additional, Bota, S., additional, Thiberville, L., additional, Gallocher, O., additional, Quoix, E., additional, Mennecier, B., additional, Jung, G.M., additional, Falchero, L., additional, Paillotin, D., additional, Schouabe, S., additional, Jonveaux, E., additional, Bout, J.C., additional, Martin, P., additional, Perol, M., additional, Arpin, D., additional, Martel-Lafay, I., additional, Letreut, J., additional, Poirier, R., additional, Benyoub, A., additional, Vernejoux, J.M., additional, Trouette, R., additional, Dansin, E., additional, Berard, H., additional, Pietra, J.C., additional, Zalcman, G., additional, Thomas, P., additional, Zribi, A., additional, Milleron, B., additional, Lavolé, A., additional, Coetmeur, D., additional, Lamezec, B., additional, Bonnamour, C., additional, Grangeon, V., additional, Suchaud, J.P., additional, Créquit, J., additional, Ramdane, S., additional, Barre, P., additional, Zawadi, M.A., additional, Gimenez, C., additional, Barlesi, F., additional, Pignon, T., additional, Grivaux, M., additional, Blanchon, F., additional, Mandet, J., additional, Perdu, D., additional, Cauchois, A., additional, Delhoume, J.Y., additional, Kin, B., additional, Merle, P., additional, Janicot, H., additional, Verrelle, P., additional, Auliac, J.B., additional, Coscas, Y., additional, Ducolone, A., additional, Herman, D., additional, and Roquette, A., additional

Published
2016
Full Text
View/download PDF

47. Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia

Author

Vandeix, E., Favard, F., Pichon, N., Delage-Corre, M., Melloni, B., and Clavel, M.

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Introduction. Bortezomib is a proteasome inhibitor indicated for the treatment of multiple myeloma patients. The most frequent side effects are gastrointestinal and neurological. Serious pulmonary complications have been described rarely. Observation. This case involves a 74-year-old man suffering from IgG Kappa myeloma treated with bortezomib, melphalan, and dexamethasone. After administering chemotherapy, the patient developed an acute respiratory distress syndrome (ARDS). A surgical pulmonary biopsy proved the existence of bronchiolitis obliterans organizing pneumonia (BOOP) lesions. Systemic corticotherapy led to a rapid improvement in the patient’s condition. Conclusion. This is the first reported histologically confirmed case of bortezomid-induced BOOP. Faced with severe respiratory symptoms in the absence of other etiologies, complications due to bortezomid treatment should be evoked and corticotherapy considered.

Published
2012
Full Text
View/download PDF

48. Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG coincidence imaging

Author

Monteil, Jacques, Vergnenègre, Alain, Bertin, F., Dalmay, François, Gaillard, Sophie, Bonnaud, F., Melloni, B., Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges (UNILIM), Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges (UNILIM), Service de Pathologie respiratoire et allergologie [CHU Limoges], and Grelier, Elisabeth

Subjects
Adult, Male, Lung Neoplasms, MESH: Tomography, Emission-Computed, MESH: Gamma Cameras, MESH: Aged, 80 and over, MESH: Fluorodeoxyglucose F18, Fluorodeoxyglucose F18, Carcinoma, Non-Small-Cell Lung, Humans, Gamma Cameras, Aged, Neoplasm Staging, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, MESH: Humans, MESH: Adult, MESH: Neoplasm Staging, MESH: Follow-Up Studies, Middle Aged, MESH: Male, MESH: Lung Neoplasms, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Neoplasm Recurrence, Local, Radiopharmaceuticals, MESH: Neoplasm Recurrence, Local, MESH: Female, MESH: Radiopharmaceuticals, MESH: Carcinoma, Non-Small-Cell Lung, Follow-Up Studies, Tomography, Emission-Computed
Abstract

International audience; The aim of this study was to compare the utility of gamma camera using a coincidence detection system imaging (CDET) with 18-fluorodeoxyglucose to conventional imaging techniques in the detection of recurrence of non-small cell lung cancer. Sixty-nine patients were randomized into two groups for follow-up after surgery from October 2000 to December 2002. Each patient was evaluated every 6 months by conventional technique imaging in group A (n=33) or CDET imaging in group B (n=36) over two years. The direct costs of each procedure were evaluated. The major endpoint was the number of recurrences or new tumours detected. The two groups were similar. A total of 25 recurrences was detected (9 in group A and 16 in group B). Overall survival was similar in the two groups. CDET imaging was more expensive. CDET imaging provides earlier detection of recurrence, but does not modify survival outcome. Further studies are necessary to demonstrate the impact, if any, of 18-FDG imaging.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results